

From: Cibulas, William (ATSDR/OADS) [wic1@cdc.gov]

Sent: 6/20/2018 12:45:05 PM

To: **Personal Matters / Ex. 6**
 (CDC/NIOSH/OD) [f **Personal Matters / Ex. 6** [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=63d3e2eae9c4acba2609baa90b0f735-Guiseppi-El]; Hines, Ronald [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=464f333922cc4aa68db2a1677122ab58-Hines, Ronald]; **Personal Matters / Ex. 6** [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ec269b1b62f14ed187c0115b1eb24e3f-James_H_Kim];

Personal Matters / Ex. 6

Annette [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=63d3e2eae9c4acba2609baa90b0f735-Guiseppi-El]; Flowers, Lynn [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1a4411c874d041b9a8badfc32b91bd70-Flowers, Lynn]; Bennett, April (NIH/NIEHS) [C **Personal Matters / Ex. 6**]; Strickland, Maria (CDC/NIOSH/OD **Personal Matters / Ex. 6**); Orme-Zavaleta, Jennifer [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3c5a111dc377411595e5b24b5d96146b-Orme-Zavaleta, Jennifer]; Matthews, Lisa [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=47122f6ad7db43b8953ac69696db9719-Matthews, Lisa]; **Personal Matters / Ex. 6** Scheuer, Amy [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=236647acdecc48d7a41063525b847e09-Scheuer, Am]; Spring, Christina M. **Personal Matters / Ex. 6** Stroup, Gene [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=3273d845949349a9a5238c9dfcc55fcc-Stroup, Gene]; Ward, Antoinette [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=eb564f228e164dfb80198476f3614f8f-Ward, Antoinette];

Personal Matters / Ex. 6 il; Miller, Aubrey (NIH/NIEHS) [E] **Personal Matters / Ex. 6** Birnbaum, Linda (NIH/NIEHS) [E] **Personal Matters / Ex. 6** **Personal Matters / Ex. 6** [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c421f94a4d20447ca67ed6ab9ee8b03 **Personal Matters / Ex. 6** Athaler@cpsc.gov; Cascio, Wayne [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a1bd931ca2f84ea8ac2f4c44538f3589-Cascio, Wayne]; Foster, Stiven [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=43d242767f304355ad415ec856988213-sfoste02];

Personal Matters / Ex. 6 Ann (CDC/NIOSH/OD) **Personal Matters / Ex. 6** Collman, Gwen (NIH/NIEHS) [E] **Personal Matters / Ex. 6** Begley, Timothy H (FDA/CFSAN) [Timothy.Begley@ **Personal Matters / Ex. 6** Thompson, Claudia (NIH/NIEHS) [E] **Personal Matters / Ex. 6** Blystone, Chad (NIH/NIEHS) [E] **Personal Matters / Ex. 6** Gray, Kimberly (NIH/NIEHS) [E] [GRAY6@niehs.nih.gov]; Schug, Thaddeus (NIH/NIEHS) **Personal Matters / Ex. 6** Fenton, Suzanne (NIH/NIEHS) [E] **Personal Matters / Ex. 6** Levito, Michael (NIH/NIEHS) [E] **Personal Matters / Ex. 6** Andrew (NIH/NIEHS) [E] **Personal Matters / Ex. 6** **Personal Matters / Ex. 6** Grevatt, Peter [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d3caa0c39ebe44cb9d3ae44da7543733-Grevatt, Peter];

Personal Matters / Ex. 6

Subject: CDC/ATSDR Toxicological Profile on Perfluoroalkyls

Attachments: ATT00001.txt

Dear Colleague:

As a valued partner of NCEH/ATSDR, we wanted to make you aware that ATSDR is releasing a Toxicological Profile (Tox Profile) on Perfluoroalkyl Substances (PFAS) for public comment. This document will include minimal risk level values (MRLs) for Perfluoroalkyls. We know that this is a topic of great interest to many of your organizations and the constituencies and communities you serve, as well as a high priority area for our Agency.

Tox Profile for Public Comment

ATSDR's Federal Notice, "Availability of Draft Toxicological Profile: Perfluoroalkyls" (docket number ATSDR-2015-0004 or the document number 2018-13385), **will be posted online on Wednesday, June 20th, 2018 at 9:00 am. The public can view the notice at www.federalregister.gov.**

The document will officially publish in the Federal Register on Thursday, June 21st, 2018. **The public can begin commenting on the notice electronic shortly after 9 am on Thursday, June 21st by visiting www.regulations.gov.**

Additional Information

To assist in answering questions, ATSDR has worked to develop an initial set of FAQs and additional web resources accessible on our website at: www.ATSDR.CDC.gov. To learn more about PFAS, or to access PFAS-related materials, please visit: <https://www.atsdr.cdc.gov/pfas/index.html>. Media requests can be referred to envhealthmedia@cdc.gov.

FAQs

What is a Tox Profile?

Congress mandates that ATSDR produce Tox Profiles that include an examination, summary, and interpretation of available studies of the health effects of a hazardous substance. The primary users of these documents are expected to be researchers and health professionals, including health assessors at the regional and state level. Profiles go to peer review (shared with experts in the field) before they are released for public comment in the Federal Register. After the comment period, ATSDR considers all comments, revises the documents, and then finalizes the profile. If there are significant revisions as a result of the public comments, the profiles are again peer reviewed before releasing as a final.

To access all current Tox Profiles please visit: <https://www.atsdr.cdc.gov/toxprofiles/index.asp>

What's new in the PFAS Tox Profile?

This draft of the PFAS Tox Profile updates minimal risk levels (MRLs, explained below) for two PFAS chemicals (PFOA and PFOS) and sets new MRLs for two additional PFAS chemicals (PFHxS and PFNA). Updated, reliable and sufficient data were published in scientific literature after the previous 2015 draft. All four MRLs in the updated version of the Tox Profile are considered draft until they have been finalized following the public comment period.

What are MRLs, and how are they used?

An MRL is an estimate of someone's daily exposure to a hazardous substance that is likely to be without appreciable risk to their health. It looks at non-cancer health effects only. MRLs are derived for different exposure periods, including: acute (about 1 to 14 days), intermediate (from 15-364 days), and chronic (exposure for more than 365 days).

MRLs are used as a screening tool that help identify exposures that could be potentially hazardous to human health. Exposure above the MRLs does not mean that health problems will occur. Instead, it is a signal to health assessors to look more closely at a particular site where exposures may be identified.

For more information on Minimal Risk Levels please visit: <https://www.atsdr.cdc.gov/mrls/index.asp>

What do we know about PFAS?

While the Perfluoroalkyls Tox Profile is available to the public, it is an in-depth scientific resource utilized primarily by public health professionals. To help answer basic questions about Perfluoroalkyl Substances (PFAS), there are additional supplemental fact sheets, FAQs, and other consumer-oriented resources available at:

<https://www.atsdr.cdc.gov/pfas/index.html>

Acting Director
Division of Toxicology and Human Health Sciences
NCEH/ATSDR
4770 Buford Hwy., Bldg. 102, 1st Floor
Atlanta, GA 30341
MS-F57
Office: 770-488-0662
Cell: Personal Matters / Ex. 6